The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna.

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

Moderna's ability to launch differentiated mRNA therapies beyond covid, ranging from prophylactic vaccines for other respiratory diseases to cancer treatments, will be key to establishing a moat ...

The company’s latest RSV vaccine is yet to show promising sales. This has weighed on MRNA ... cancer. The vaccine also cut the risk of recurrence or death by 44%, versus Keytruda alone. Moderna ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ... and other mRNA vaccine developers, claiming they infringed on their Lipid NanoParticle ("LNP") patents.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher ... If you can use AI to make custom vaccines and cures for cancer, that could be a tremendous value to society and Moderna's ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More on MRNA: Moderna NewsMORE ...

The analyst cut her price target on MRNA to $51 from $99. A Potential Silver Lining for Moderna On a positive note, Richter believes that Moderna’s personalized cancer vaccine can boost the firm ...